Bisphosphonate use in the treatment of Paget's disease of the bone: Analysis of claims in a large database

Managed Care Interface

Volumn 20, Issue 2, 2007, Pages 33-40

  Dolgitser, Margarita ^a   Stern, Lee ^a,b,d   Katz, Laura M ^b   Doyle, Joan J ^b   Omar, Mohamed ^c   Seton, Margaret ^e   Kahler, Kristijan H ^c  

^a Global Health Outcomes   (United States)

^b Analytica International   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; COMORBIDITY; COST OF ILLNESS; DRUG COST; DRUG USE; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OSTEOPOROSIS; PAGET BONE DISEASE; TREATMENT DURATION;

AGED; DIPHOSPHONATES; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; OSTEITIS DEFORMANS; OUTCOME ASSESSMENT (HEALTH CARE); UNITED STATES;

EID: 33947167663     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Siris E, Weistein RS, Altman R, et al: Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996;81:961-967.
2. Siris ESL: Paget's disease of bone, in Fauvus MJ (ed): Primer on the Metabolic Bone Disease and Disorders of Bone Metabolism. New York, Raven Press, 1993; 375-384.
3. Selby PL, Davie MWJ, Ralston SH, et al: Guidelines on the management of Paget's disease of the bone. Bone 2002;31:10-19.
4. Altman RD, Bloch DA, Hochberg MC, et al: Prevalence of pelvic Paget's disease of bone in the United States. J Bone Miner Res 2000;15:461-465.
5. Carbone L: Paget disease. EMedicine (www.emedicine.com/ med/topic2998.htm), 2002.
6. Briesacher BA, Orwig D, Seton M, et al: Medical care costs of Paget's disease of bone in a privately insured population. Bone 2006;38:731-737.
7. Eekhoff ME, Zwinderman AH, Haverkort DM, et al: Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy. Bone 2003; 33:831-838.
8. Patel S, Stone MD, Coupland C, et al: Determinants of remission of Paget's disease of bone. J Bone Miner Res 1993;8:1467-1473.
9. Fleisch H: Experimental basis for the use of bisphosphonates in Paget's disease of bone. Clin Orthol 1987;217:72-80.
10. Reid IR, Miller P, Lyles K, et al: Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005;53:872-875.
11. Reid I, Miller P, Brown J, et al: A single dose of zoledronic acid 5 mg achieves more sustained biochemical remission than risedronate 30 mg in patients with Paget's disease. Presented at the 6th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. Vienna, Austria, March 15-18, 2006.
12. Fosamax (alendronate sodium tablets and oral solution) prescribing information. Whitehouse Station, NJ, Merck & Co., Inc., July 2005.
13. Didronel (etidronate disodium) prescribing information. Mason, OH, Proctor and Gamble Pharmaceuticals, May 2005.
14. Aredia (pamidronate disodium for injection) prescribing information. East Hanover, NJ, Novartis Pharmaceuticals Corp., April 2005.
15. Actonel (risedronate sodium tablets) prescribing information. Kansas City, MO, Aventis Pharmaceuticals, Inc., May 2005.
16. Skelid (tiludronate disodium) prescribing information. New York, Sanofi-Synthelabo, Inc., October 2003.
17. Marcus P, Oppenheimer EA, Patel PA, et al: Use of nebulized inhaled corticosteroids among older adult patients: An assessment of outcomes. Ann Allergy Asthma Immunol 2006;96:736-743.
18. International Classification of Diseases, 9th Revision, Clinical Modification. Ed. 5. Los Angeles, Medicode Publications, 1999.
19. Redbook. Redbook for Windows, version 5.0. Greenwood Village, CO, Micromedex, Inc., 2004.
20. CPT Plus. A Comprehensive Guide to Current Procedural Terminology. Los Angeles, Practice Management Information Corp., 2003.
21. McGavock, H: Prescription-related illness: A scandalous pandemic. J Eval Clin Pract 2004;10:491-497.